Compare ORGO & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORGO | BME |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.6M | 547.5M |
| IPO Year | 2016 | 2005 |
| Metric | ORGO | BME |
|---|---|---|
| Price | $2.64 | $39.72 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | ★ 686.0K | 36.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1600.00 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $564,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.84 | N/A |
| P/E Ratio | $17.67 | ★ N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $2.61 | $34.18 |
| 52 Week High | $7.08 | $42.74 |
| Indicator | ORGO | BME |
|---|---|---|
| Relative Strength Index (RSI) | 23.16 | 22.68 |
| Support Level | $2.61 | $35.48 |
| Resistance Level | $5.08 | $42.55 |
| Average True Range (ATR) | 0.22 | 0.59 |
| MACD | -0.05 | -0.26 |
| Stochastic Oscillator | 0.66 | 0.00 |
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.